tetano
Editor, Senior Moderator
Br J Haematol
. 2022 Nov 10.
doi: 10.1111/bjh.18547. Online ahead of print.
Safety of coronavirus disease 2019 vaccines in 213 adult patients with sickle cell disease
Laure Joseph[SUP] 1 2 [/SUP], Anne Corbasson[SUP] 3 [/SUP], Sandra Manceau[SUP] 1 2 [/SUP], Djamal Khimoud[SUP] 3 [/SUP], Benoit Meunier[SUP] 1 [/SUP], Geoffrey Cheminet[SUP] 3 4 [/SUP], François Lefrere[SUP] 1 [/SUP], Anne-Sophie Jannot[SUP] 4 5 [/SUP], Estelle Lu[SUP] 5 [/SUP], Jean-Benoît Arlet[SUP] 2 3 4 6 [/SUP]
Affiliations
Abstract
Given the lack of information about safety of the COVID-19 vaccines for sickle cell disease (SCD) patients, we sought to determine whether COVID-19 vaccine was associated with subsequent hospital admission for vaso-occlusive events (VOEs). We included 402 patients with SCD, including 88 regularly transfused. As of July 31, 2021, 213 (53.0%) of them had received a least one dose of COVID vaccine (Pfizer 93.0%). We showed similar risk of hospital admission for a VOE among vaccinated patients (whether transfused or not) and among a control group of non-vaccinated patients matched for age, sex and genotype.
Keywords: coronavirus disease 2019 vaccine; hospital admission; safety; sickle cell disease; vaccination.
. 2022 Nov 10.
doi: 10.1111/bjh.18547. Online ahead of print.
Safety of coronavirus disease 2019 vaccines in 213 adult patients with sickle cell disease
Laure Joseph[SUP] 1 2 [/SUP], Anne Corbasson[SUP] 3 [/SUP], Sandra Manceau[SUP] 1 2 [/SUP], Djamal Khimoud[SUP] 3 [/SUP], Benoit Meunier[SUP] 1 [/SUP], Geoffrey Cheminet[SUP] 3 4 [/SUP], François Lefrere[SUP] 1 [/SUP], Anne-Sophie Jannot[SUP] 4 5 [/SUP], Estelle Lu[SUP] 5 [/SUP], Jean-Benoît Arlet[SUP] 2 3 4 6 [/SUP]
Affiliations
- PMID: 36354234
- DOI: 10.1111/bjh.18547
Abstract
Given the lack of information about safety of the COVID-19 vaccines for sickle cell disease (SCD) patients, we sought to determine whether COVID-19 vaccine was associated with subsequent hospital admission for vaso-occlusive events (VOEs). We included 402 patients with SCD, including 88 regularly transfused. As of July 31, 2021, 213 (53.0%) of them had received a least one dose of COVID vaccine (Pfizer 93.0%). We showed similar risk of hospital admission for a VOE among vaccinated patients (whether transfused or not) and among a control group of non-vaccinated patients matched for age, sex and genotype.
Keywords: coronavirus disease 2019 vaccine; hospital admission; safety; sickle cell disease; vaccination.